729 related articles for article (PubMed ID: 20679882)
1. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH
Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882
[TBL] [Abstract][Full Text] [Related]
2. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
[TBL] [Abstract][Full Text] [Related]
3. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.
Finley DS; Shuch B; Said JW; Galliano G; Jeffries RA; Afifi AA; Castor B; Magyar C; Sadaat A; Kabbinavar FF; Belldegrun AS; Pantuck AJ
J Urol; 2011 Dec; 186(6):2168-74. PubMed ID: 22014797
[TBL] [Abstract][Full Text] [Related]
4. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma.
Delahunt B; Sika-Paotonu D; Bethwaite PB; McCredie MR; Martignoni G; Eble JN; Jordan TW
Am J Surg Pathol; 2007 Jun; 31(6):957-60. PubMed ID: 17527087
[TBL] [Abstract][Full Text] [Related]
5. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.
Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC
Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296
[TBL] [Abstract][Full Text] [Related]
6. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma.
Ficarra V; Martignoni G; Maffei N; Brunelli M; Novara G; Zanolla L; Pea M; Artibani W
Cancer; 2005 Jan; 103(1):68-75. PubMed ID: 15573369
[TBL] [Abstract][Full Text] [Related]
7. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients.
Gudbjartsson T; Hardarson S; Petursdottir V; Thoroddsen A; Magnusson J; Einarsson GV
Eur Urol; 2005 Oct; 48(4):593-600. PubMed ID: 15964127
[TBL] [Abstract][Full Text] [Related]
8. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
9. Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma.
Ku JH; Moon KC; Kwak C; Kim HH
Urol Oncol; 2011; 29(5):487-91. PubMed ID: 19767221
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype.
Delahunt B; Bethwaite PB; Nacey JN
Pathology; 2007 Oct; 39(5):459-65. PubMed ID: 17886093
[TBL] [Abstract][Full Text] [Related]
11. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.
Przybycin CG; Cronin AM; Darvishian F; Gopalan A; Al-Ahmadie HA; Fine SW; Chen YB; Bernstein M; Russo P; Reuter VE; Tickoo SK
Am J Surg Pathol; 2011 Jul; 35(7):962-70. PubMed ID: 21602658
[TBL] [Abstract][Full Text] [Related]
12. Prognostic ability of simplified nuclear grading of renal cell carcinoma.
Rioux-Leclercq N; Karakiewicz PI; Trinh QD; Ficarra V; Cindolo L; de la Taille A; Tostain J; Zigeuner R; Mejean A; Patard JJ
Cancer; 2007 Mar; 109(5):868-74. PubMed ID: 17262800
[TBL] [Abstract][Full Text] [Related]
13. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up.
Lang H; Lindner V; de Fromont M; Molinié V; Letourneux H; Meyer N; Martin M; Jacqmin D
Cancer; 2005 Feb; 103(3):625-9. PubMed ID: 15611969
[TBL] [Abstract][Full Text] [Related]
14. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
15. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
Sengupta S; Lohse CM; Leibovich BC; Frank I; Thompson RH; Webster WS; Zincke H; Blute ML; Cheville JC; Kwon ED
Cancer; 2005 Aug; 104(3):511-20. PubMed ID: 15973740
[TBL] [Abstract][Full Text] [Related]
16. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma.
Sika-Paotonu D; Bethwaite PB; McCredie MR; William Jordan T; Delahunt B
Am J Surg Pathol; 2006 Sep; 30(9):1091-6. PubMed ID: 16931953
[TBL] [Abstract][Full Text] [Related]
17. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence.
Delahunt B; Sika-Paotonu D; Bethwaite PB; William Jordan T; Magi-Galluzzi C; Zhou M; Samaratunga H; Srigley JR
Am J Surg Pathol; 2011 Aug; 35(8):1134-9. PubMed ID: 21716085
[TBL] [Abstract][Full Text] [Related]
18. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.
Steffens S; Janssen M; Roos FC; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Hasenfus A; Kuczyk MA; Junker K; Schrader AJ;
Hum Pathol; 2014 Dec; 45(12):2411-6. PubMed ID: 25305793
[TBL] [Abstract][Full Text] [Related]
19. Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma.
Serrano MF; Katz M; Yan Y; Kibel AS; Humphrey PA
Cancer; 2008 Aug; 113(3):477-83. PubMed ID: 18484589
[TBL] [Abstract][Full Text] [Related]
20. Proposal for revision of the TNM classification system for renal cell carcinoma.
Ficarra V; Guillè F; Schips L; de la Taille A; Prayer Galetti T; Tostain J; Cindolo L; Novara G; Zigeuner R; Bratti E; Li G; Altieri V; Abbou CC; Zanolla L; Artibani W; Patard JJ
Cancer; 2005 Nov; 104(10):2116-23. PubMed ID: 16208703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
